Assignee
FIBROGEN INC
US·57 granted patents·61 pending applications·961 citations·filing 1995–2023
Top patents by PatentIndex Score
118 records- 0198US7323475B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2004·Granted Jan 29, 2008·97 cites·46 claims
- 0298US6992172B1Recombinant gelatinsFIBROGEN INC·Filed 2000·Granted Jan 31, 2006·229 cites·47 claims
- 0397US8883823B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2013·Granted Nov 11, 2014·20 cites·52 claims
- 0497US7629357B2Nitrogen-containing heteroaryl compounds and methods of user thereofFIBROGEN INC·Filed 2006·Granted Dec 8, 2009·38 cites·52 claims
- 0596US8017625B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2008·Granted Sep 13, 2011·42 cites·47 claims
- 0696US7863292B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2007·Granted Jan 4, 2011·28 cites·38 claims
- 0795US10626090B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2017·Granted Apr 21, 2020·6 cites·10 claims
- 0895US8765956B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2013·Granted Jul 1, 2014·19 cites·19 claims
- 0995US7928120B2Cyanoisoquinoline compounds and methods of use thereofFIBROGEN INC·Filed 2007·Granted Apr 19, 2011·40 cites·36 claims
- 1095US7696223B2Pyrrolo- and Thiazolo-pyridine compounds, and methods of use thereofFIBROGEN INC·Filed 2007·Granted Apr 13, 2010·54 cites·32 claims
- 1193US10927081B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2018·Granted Feb 23, 2021·3 cites·46 claims
- 1293US10894774B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2017·Granted Jan 19, 2021·3 cites·23 claims
- 1393US10882827B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2018·Granted Jan 5, 2021·3 cites·24 claims
- 1493US9371288B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2014·Granted Jun 21, 2016·7 cites·5 claims
- 1593US7405274B2Connective tissue growth factor antibodiesFIBROGEN INC·Filed 2004·Granted Jul 29, 2008·47 cites·28 claims
- 1692US9920011B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2013·Granted Mar 20, 2018·10 cites·6 claims
- 1792US9695170B2Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylaseFIBROGEN INC·Filed 2016·Granted Jul 4, 2017·5 cites·32 claims
- 1892US9115085B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2013·Granted Aug 25, 2015·12 cites·11 claims
- 1992US7871617B2Antibodies that bind to a portion of the VWC domain of connective tissue growth factorFIBROGEN INC·Filed 2008·Granted Jan 18, 2011·16 cites·45 claims
- 2091US9340511B2Process for making isoquinoline compoundsFIBROGEN INC·Filed 2013·Granted May 17, 2016·16 cites·48 claims
- 2191US9271970B2Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylaseFIBROGEN INC·Filed 2014·Granted Mar 1, 2016·7 cites·30 claims
- 2291US7713986B2Compounds and methods for treatment of chemotherapy-induced anemiaFIBROGEN INC·Filed 2006·Granted May 11, 2010·17 cites·8 claims
- 2390US9339527B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2014·Granted May 17, 2016·7 cites·20 claims
- 2489US11680048B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2020·Granted Jun 20, 2023·1 cites·14 claims
- 2589US11680047B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2020·Granted Jun 20, 2023·1 cites·23 claims
- 2689US9918977B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2016·Granted Mar 20, 2018·3 cites·13 claims
- 2789US7618940B2Fat regulationFIBROGEN INC·Filed 2003·Granted Nov 17, 2009·35 cites·16 claims
- 2889US7393928B2Recombinant gelatinsFIBROGEN INC·Filed 2005·Granted Jul 1, 2008·11 cites·24 claims
- 2988US10272078B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2018·Granted Apr 30, 2019·2 cites·6 claims
- 3088US9617218B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2015·Granted Apr 11, 2017·5 cites·6 claims
- 3188US9387200B2Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activityFIBROGEN INC·Filed 2015·Granted Jul 12, 2016·5 cites·17 claims
- 3288US9174976B2Cyanoisoquinoline compounds and methods of use thereofFIBROGEN INC·Filed 2014·Granted Nov 3, 2015·9 cites·41 claims
- 3387US10092558B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2016·Granted Oct 9, 2018·3 cites·20 claims
- 3487US9708269B2Process for making isoquinoline compoundsFIBROGEN INC·Filed 2016·Granted Jul 18, 2017·6 cites·9 claims
- 3587US2024182424A1Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2023·Application pending·0 cites
- 3685US9000006B2Thienopyridine compounds, and methods of use thereofFIBROGEN INC·Filed 2014·Granted Apr 7, 2015·7 cites·14 claims
- 3784US9149476B2Thiochromene derivatives as HIF hydroxylase inhibitorsFIBROGEN INC·Filed 2014·Granted Oct 6, 2015·7 cites·37 claims
- 3884US2024076364A1Connective tissue growth factor antibodiesFIBROGEN INC·Filed 2022·Application pending·0 cites
- 3982US10118897B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2017·Granted Nov 6, 2018·2 cites·18 claims
- 4081US9631013B2Therapeutic method for pancreatic cancerFIBROGEN INC·Filed 2015·Granted Apr 25, 2017·6 cites·6 claims
- 4180US9643928B2Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acidFIBROGEN INC·Filed 2014·Granted May 9, 2017·4 cites·39 claims
- 4280US9409892B24-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitorsFIBROGEN INC·Filed 2013·Granted Aug 9, 2016·6 cites·30 claims
- 4379US10039515B2Methods for treating idiopathic pulmonary fibrosisFIBROGEN INC·Filed 2016·Granted Aug 7, 2018·3 cites·5 claims
- 4479US2021369702A1Methods for treating anemia in subjects having kidney failure using inhibitors of hypoxia-inducible factor (hif) hydroxylaseFIBROGEN INC·Filed 2021·Application pending·0 cites
- 4576US10765672B2Pharmaceutical formulations of a HIF hydroxylase inhibitorFIBROGEN INC·Filed 2018·Granted Sep 8, 2020·2 cites·6 claims
- 4676US6462063B1C-proteinase inhibitorsFIBROGEN INC·Filed 2000·Granted Oct 8, 2002·10 cites·28 claims
- 4776US6358741B1Connective tissue growth factor (CTGF) and methods of useFIBROGEN INC·Filed 1999·Granted Mar 19, 2002·40 cites·16 claims
- 4875US11229637B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2020·Granted Jan 25, 2022·0 cites·12 claims
- 4975US9034643B2Connective tissue growth factor antibodiesFIBROGEN INC·Filed 2012·Granted May 19, 2015·1 cites·12 claims
- 5075US6555322B1α2-macroglobulin receptor as a receptor for CTGFFIBROGEN INC·Filed 2000·Granted Apr 29, 2003·6 cites·7 claims
Showing the top 50 of 118 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →